Literature DB >> 8198871

Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251.

K A Kent1, P Kitchin, K H Mills, M Page, F Taffs, T Corcoran, P Silvera, B Flanagan, C Powell, J Rose.   

Abstract

In the first of two passive transfer experiments, three groups of four macaques were injected intraperitoneally with a normal serum pool, an immune serum pool (pool 1) collected 132-172 weeks postinfection with the 11/88 pool of SIVmac251, or with a pool of four neutralizing monoclonal antibodies (KK9, 17, 54, and 56) raised against gp120 of the 11/88 pool. Sera were given at a dose of 13 ml/kg whereas the MAb pool was given at 30 ml/kg. In a second experiment, a further four macaques were injected with an immune serum pool (pool 2) collected 12 weeks postinfection with simian-grown SIVmac251 at a dose of 19 ml/kg. Animals in both experiments were challenged with SIVmac251 grown in simian peripheral blood lymphocytes. Despite high levels of circulating antibodies in the serum of animals that received either the immune serum pools or the MAbs, all macaques became infected following challenge. The results described are in contrast to a previous report in which passive transfer of sera from animals infected with SIVsm successfully protected against challenge with the homologous virus grown in human PBMCs. Challenge with SIVmac251 grown in simian PBMCs may be the reason for these conflicting results. Nevertheless, the results suggest that in this model the presence of circulating neutralizing antibodies alone does not necessarily confer protection against challenge with SIVmac251 grown in simian cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198871     DOI: 10.1089/aid.1994.10.189

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

Authors:  J Glamann; V M Hirsch
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  A vaccine for HIV type 1: the antibody perspective.

Authors:  D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

Authors:  E Jurkiewicz; G Hunsmann; J Schäffner; T Nisslein; W Lüke; H Petry
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus.

Authors:  Richard Stebbings; Neil Berry; Herman Waldmann; Pru Bird; Geoff Hale; Jim Stott; David North; Robin Hull; Joanna Hall; Jenny Lines; Stuart Brown; Nikki D'Arcy; Leanne Davis; William Elsley; Cherry Edwards; Deborah Ferguson; Jane Allen; Neil Almond
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.

Authors:  J Glamann; D R Burton; P W Parren; H J Ditzel; K A Kent; C Arnold; D Montefiori; V M Hirsch
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.

Authors:  A Li; H Katinger; M R Posner; L Cavacini; S Zolla-Pazner; M K Gorny; J Sodroski; T C Chou; T W Baba; R M Ruprecht
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.